Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn.
OBJECTIVE
To determine the clinical role of inhaled nitric oxide (iNO) in the treatment of persistent pulmonary hypertension of the newborn (PPHN).


METHODS
Prospective open observational clinical study.


METHODS
A regional cardiac and pediatric intensive care unit.


METHODS
Twenty-five consecutive near-term neonates (> 35 weeks gestation) with severe PPHN (oxygenation index [OI] > 25) were given a trial of iNO of 20 ppm for 20 minutes. Neonates who showed a greater than 20% improvement in PaO2 as well as a decrease in the OI to below 40 were defined as responders and continued on this therapy.


RESULTS
Four patterns of response emerged to the iNO therapy: Pattern 1 neonates (n = 2) did not respond to the initial trial of iNO-one survived. Pattern 2 neonates (n = 9) responded to the initial trial of iNO, but failed to sustain this response over 36 hours, as defined by a rise in the OI to > 40. Six survived, five with extracorporeal membrane oxygenation. Pattern 3 neonates (n = 11) responded to the initial trial of iNO, sustained this response, and were successfully weaned from iNO within 5 days--all survived to discharge. Pattern 4 neonates (n = 3) responded to the initial trial of iNO, but developed a sustained dependence on iNO for 3 to 6 weeks. All three died and lung histology revealed severe pulmonary hypoplasia and dysplasia. These neonates (pattern 4) not only required iNO for a longer period of time than did the sustained responders (pattern 3), but they required significantly higher doses of iNO during their first 5 days of iNO therapy.


CONCLUSIONS
Early responses to iNO may not be sustained. Neonates with pulmonary hypoplasia and dysplasia may have a decreased sensitivity and differing time course of response to iNO when compared with patients who have PPHN in fully developed lungs.
Goldman
A P
AP
Cardiac Unit, Great Ormond Street Hospital for Children, London, United Kingdom.
Tasker
R C
RC
Haworth
S G
SG
Sigston
P E
PE
Macrae
D J
DJ
D000280:Administration, Inhalation; D001706:Biopsy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000002:abnormalities / Q000473:pathology; D008297:Male; D009569:Nitric Oxide / Q000008:administration & dosage* / Q000009:adverse effects; D010547:Persistent Fetal Circulation Syndrome / Q000188:drug therapy* / Q000473:pathology; D011446:Prospective Studies; D012121:Respiration, Artificial; D019141:Respiratory System Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D019141:Respiratory System Agents; D009569:Nitric Oxide